2014
Systems Immunology Reveals Markers of Susceptibility to West Nile Virus Infection
Qian F, Goel G, Meng H, Wang X, You F, Devine L, Raddassi K, Garcia MN, Murray KO, Bolen CR, Gaujoux R, Shen-Orr SS, Hafler D, Fikrig E, Xavier R, Kleinstein SH, Montgomery RR. Systems Immunology Reveals Markers of Susceptibility to West Nile Virus Infection. MSphere 2014, 22: 6-16. PMID: 25355795, PMCID: PMC4278927, DOI: 10.1128/cvi.00508-14.Peer-Reviewed Original ResearchConceptsWest Nile virus infectionVirus infectionMyeloid dendritic cellsMarker of susceptibilityPotential therapeutic strategySeverity of infectionSevere neurological diseaseOlder patientsAcute infectionDendritic cellsCXCL10 expressionDetectable yearsImmunity-related genesStratified cohortWNV infectionTherapeutic strategiesPathogenic mechanismsAnimal studiesNeurological diseasesDisease severityVivo infectionPredictive signatureInfectionProminent alterationsPrimary cells
1992
Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction
Krumholz H, Pasternak R, Weinstein M, Friesinger G, Ridker P, Tosteson A, Goldman L. Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction. New England Journal Of Medicine 1992, 327: 7-13. PMID: 1598117, DOI: 10.1056/nejm199207023270102.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionThrombolytic therapyRisk of deathMyocardial infarctionElderly patientsPatients 75 yearsST-segment elevationOnset of symptomsUse of streptokinaseOne-way sensitivity analysesDecision analytic modelYears of lifeCost-effective treatmentRelative reductionHospital deathStreptokinase therapyOlder patientsClinical circumstancesThrombolytic agentsInfarctionPatientsCost effectivenessTherapyLack of consensusStreptokinase